Labcorp Inc.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-inf...
Latest News
2 days ago · zacks.com
Labcorp Holdings (LH) is a Top-Ranked Value Stock: Should You Buy?Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
4 days ago · seekingalpha.com
Labcorp Holdings: The Optimism May Be Going Overboard (Rating Downgrade)Labcorp Holdings raised guidance, triggering a sharp stock price rally. I view LH as a compelling long-term growth story, but current valuation is stretched. The price-earnings ratio approaching 20 exceeds my preferred range for LH's fundamentals.
4 days ago · seekingalpha.com
Labcorp Holdings Inc. (LH) Q3 2026 Earnings Call TranscriptLabcorp Holdings Inc. (LH) Q3 2026 Earnings Call Transcript
4 days ago · benzinga.com
Labcorp Targets Margin Growth, Absorbs Policy HeadwindsLabcorp Holdings (NYSE:LH) stock is trading at a 52-week high after the company reported upbeat third-quarter earnings and raised its fiscal outlook.
4 days ago · marketbeat.com
Labcorp Q3 Earnings Call HighlightsLabcorp NYSE: LH reported third-quarter 2026 revenue growth, margin expansion and double-digit adjusted earnings-per-share growth, prompting the laboratory services company to raise the midpoint of its full-year revenue and earnings outlook.
4 days ago · zacks.com
LH Stock Rises on Q3 Earnings and Revenue Beat, '26 View UpLabcorp shares rise as Q3 earnings and revenues beat estimates, both segments deliver growth, margins expand and the company raises its 2026 financial outlook.
4 days ago · zacks.com
Compared to Estimates, Labcorp (LH) Q3 Earnings: A Look at Key MetricsAlthough the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
5 days ago · zacks.com
Labcorp Holdings (LH) Q3 Earnings and Revenues Surpass EstimatesLabcorp Holdings (LH) came out with quarterly earnings of $4.78 per share, beating the Zacks Consensus Estimate of $4.65 per share. This compares to earnings of $4.18 per share a year ago.
5 days ago · prnewswire.com
Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 GuidanceResults from operations for third quarter 2026 versus third quarter 2025: Revenue: $3.81 billion vs. $3.56 billion, up 6.9% Diluted EPS: $3.22 vs.
11 days ago · prnewswire.com
Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse PotentialResearch collaboration aims to strengthen the science used to assess whether new medicines could be abused, supporting safer drug development and more informed regulatory decisions BURLINGTON, N.C., Oct. 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the U.S. Food and Drug Administration (FDA) and Charles River Laboratories to advance the science used to evaluate a medicine's abuse potential, or the likelihood that it could be abused.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove LH